Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04529005 · ClinicalTrials.gov registry record · Phase 4
Angiotensin II in the Perioperative Management of Hypotension in Kidney Transplant Recipients
A Phase 4 study, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT04529005 is a Phase 4 study that has completed, run by University of Illinois at Chicago. The registered enrollment target is 20 participants.
The verdict
NCT04529005, a Phase 4 study, has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
The current standard of catecholamine vasopressor management of perioperative hypotension in kidney transplant patients carries significant risks and falls short in many ways. Currently, there is an absence in the scientific literature and research describing the hemodynamic effectiveness and safety of novel pharmacologic agents such as angiotensin II (Giapreza - Ang II) in perioperative kidney transplant patients. Phase 3 registration trials have demonstrated the superior safety and efficacy of Ang II (Giapreza) in distributive shock patients compared to traditional vasopressor agents and the novel mechanism of action may provide additional protection in renal transplant patients. The pilot study entails giving informed and consenting kidney transplant recipients Ang II (Giapreza) as their first vasopressor if the need for vasopressors emerge either intraoperatively or postoperatively in kidney transplant recipients. The primary objective is to evaluate the safety and hemodynamic effects of Ang II (Giapreza) in the renal transplant population.
Interventions
- DRUG Angiotensin II
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-08-13 |
| Est. Completion | 2021-08-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04529005
The ClinicalTrials.gov registry entry for NCT04529005 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Angiotensin II is the first listed.
NCT04529005 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04529005 about?
NCT04529005 is a clinical study titled "Angiotensin II in the Perioperative Management of Hypotension in Kidney Transplant Recipients". The current standard of catecholamine vasopressor management of perioperative hypotension in kidney transplant patients carries significant risks and falls short in many ways. Currently, there is an absence in the scientific literature and research describing the hemodynamic effectiveness and safety...
What is the current status of trial NCT04529005?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2020-08-13. Estimated completion is 2021-08-01.
What interventions are being tested in trial NCT04529005?
The interventions under investigation include: Angiotensin II (DRUG).
Who is sponsoring clinical trial NCT04529005?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.